

MOMENTA PHARMACEUTICALS INC  
Form 8-K  
October 19, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 17, 2016

Momenta Pharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter)

Delaware                                      000-50797                                      04-3561634  
(State or other jurisdiction              (Commission File Number) (IRS Employer Identification No.)  
of incorporation)

675 West Kendall Street, Cambridge, MA 02142  
(Address of principal executive offices)              (Zip Code)

Registrant's telephone number, including area code: (617) 491-9700

Not applicable  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 17, 2016, James M. Roach, M.D., informed Momenta Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his roles as the Company's Senior Vice President, Development and Chief Medical Officer, effective on or around November 29, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MOMENTA  
PHARMACEUTICALS, INC.

Date: October 19, 2016 By: /s/ Richard P. Shea  
Richard P. Shea  
Chief Financial Officer  
(Principal Financial Officer)